Search results
Added:
5 months ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device…
View more
Added:
7 months ago
Presented at the European Society of Cardiology (ESC) Congress 2025, Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Stanford, US) and Prof Jeffrey Weitz (Hamilton, CA) examine the prevalence and challenges of stroke prevention in atrial fibrillation (AF) and after acute coronary syndrome (ACS). The faculty review current treatment guidelines, explore…
View more
Added:
7 months ago
Hear from Prof Carolyn Lam and Prof Jeffrey Weitz as they share key take-home messages from ESC 2025.Filmed onsite, this peer-to-peer discussion distils the latest updates in thrombosis management for acute coronary syndrome (ACS), secondary stroke prevention (SSP) and atrial fibrillation (AF).Register for the upcoming Q&A webinar, taking place on 6 October (14:00 EDT / 20:00 CEST), to put your…
View more
Start date:
Oct 06, 2025
Following the ESC 2025 symposium 'Revolutionising Thrombosis Treatment in ACS, SSP and AF – Bridging the Gaps With Next Generation Anticoagulation Strategies', this live Q&A webinar offers an exclusive chance to continue the conversation.Join Prof Carolyn Lam (Singapore, UK), Prof Jeffrey Weitz (Hamilton, CA) and Dr Sneha Shah Jain (Stanford, US) as they address your questions on stroke…
View more
Added:
1 year ago
ACC 25 - Findings from a stratified study investigating coronary stenting and bleeding risk suggest 3 months are the optimal duration of DAPT after PCI.Dr Hyo-Soo Kim (Seoul National University Hospital, KR) sits down to discuss the first randomized study stratifying patients receiving percutaneous coronary intervention with drug eluting stents according to bleeding risk based on the ARC HBR…
View more
Added:
11 months ago
EuroPCR 25 - 10-year follow-up findings of DANAMI-3-DEFER show a deferred stenting strategy may reduce HF hospitalisation in ST-elevation myocardial infarction (STEMI) patients.We are joined by Dr Jacob Lønborg (Rigshospitalet, Copenhagen, DK) to discuss key findings from the 10-year follow-up of the DANAMI-3-DEFER (NCT01435408) trial. This randomized controlled trial compared deferred stent…
View more
Added:
1 year ago
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary…
View more
Added:
1 year ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the…
View more
Added:
11 months ago
EuroPCR 25 - Subgroup analysis outcomes from OCCUPI show optical coherence tomography-guided percutaneous coronary intervention (PCI) is an effective intravascular imaging technique for complex lesions, having successfully met its composite primary outcome measure.We are joined by Dr Byeong-Keuk Kim (Yonsei University College of Medicine, Seoul, KR) to discuss subgroup analysis findings from the…
View more
Added:
1 month ago
Source:
Arrhythmia Academy
In atrial fibrillation (AF) patients post one-year drug-eluting stent (DES) implantation, non–vitamin K antagonist oral anticoagulant (NOAC) was shown to be noninferior to NOAC plus clopidogrel combination therapy.¹ Current guidelines recommend NOAC monotherapy in this patient population, but supporting evidence has been limited.²MethodologyThe ADAPT AF-DES trial was a multicenter, randomised,…
View more